 |
Jerusalem, Israel, Lund, Sweden, February 8, 2010
Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regions
|
|
Jerusalem, February 5, 2010
Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
|
|
Jerusalem, February 2, 2010
Teva Announces FDA Accepts BLA for XM02
|
|
Jerusalem, Israel, January 26, 2010
Teva Receives Favorable Court Decision Regarding Generic Temodar®
|
|
Jerusalem, Israel, January 22, 2010
Court of Appeals Affirms Favorable Decision Regarding Generic Prevacid® SoluTab
|
|
Jerusalem, Israel, January 21, 2010
Teva Announces Tentative Approval of Generic Femara® Tablets
|
|
Jerusalem, Israel, January 19, 2010
Teva to Donate Medicine to Haiti Earthquake Relief Effort
|
|
Jerusalem, Israel, January 19, 2010
Teva to Report Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010
|
|
Jerusalem, Israel, January 14, 2010
Moody's Upgrades Teva Rating to A3
|
|
Jerusalem, Israel, January 8, 2010
Teva To Present At The 28th Annual J.P. Morgan Healthcare Conference
|
|
Jerusalem, Israel, January 7, 2010
Teva Presents Strategic Plan to Deliver Strong Growth
|
|
Jerusalem, Israel, January 7, 2010
Teva Announces Settlement Agreements With AstraZeneca Regarding Generic Prilosec® and Nexium®
|
|
Jerusalem, Israel, January 4, 2010
Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
|
